These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38392856)

  • 41. A High-Fat/High-Protein, Atkins-Type Diet Exacerbates
    Mefferd CC; Bhute SS; Phan JR; Villarama JV; Do DM; Alarcia S; Abel-Santos E; Hedlund BP
    mSystems; 2020 Feb; 5(1):. PubMed ID: 32047064
    [No Abstract]   [Full Text] [Related]  

  • 42. Challenges in the Diagnosis and Management of Recurrent and Severe Clostridioides difficile Infection in Children.
    Sattler MM; Crews JD
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S27-S33. PubMed ID: 34791399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature.
    Adams DJ; Barone JB; Nylund CM
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S22-S26. PubMed ID: 34791398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Host Immunity and Immunization Strategies for Clostridioides difficile Infection.
    Naz F; Petri WA
    Clin Microbiol Rev; 2023 Jun; 36(2):e0015722. PubMed ID: 37162338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.
    Hu X; Dong R; Huang S; Zeng Y; Zhan W; Gao X; Tian D; Peng J; Xu J; Wang T; Zhang Y; Wang X; Zhang X; Liu J; Guang B; Yang T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170422. PubMed ID: 37052498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 48. Increasing prevalence of the epidemic ribotype 106 in healthcare facility-associated and community-associated Clostridioides difficile infection.
    Suárez-Bode L; Barrón R; Pérez JL; Mena A
    Anaerobe; 2019 Feb; 55():124-129. PubMed ID: 30550807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The microbial metabolite urolithin A reduces
    Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
    mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
    [No Abstract]   [Full Text] [Related]  

  • 50.
    Wang R
    Front Microbiol; 2023; 14():1182612. PubMed ID: 37228365
    [No Abstract]   [Full Text] [Related]  

  • 51. Clostridioides difficile infection (CDI) during the COVID-19 pandemic.
    Spigaglia P
    Anaerobe; 2022 Apr; 74():102518. PubMed ID: 35063599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.
    Winston JA; Rivera AJ; Cai J; Thanissery R; Montgomery SA; Patterson AD; Theriot CM
    Infect Immun; 2020 May; 88(6):. PubMed ID: 32205405
    [No Abstract]   [Full Text] [Related]  

  • 53. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.
    Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM
    mBio; 2020 Mar; 11(2):. PubMed ID: 32156806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spore-Forming
    Chisholm JM; Putsathit P; Riley TV; Lim SC
    Microbiol Spectr; 2023 Feb; 11(1):e0358222. PubMed ID: 36475924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fecal Microbiota of Toxigenic
    Hernández M; de Frutos M; Rodríguez-Lázaro D; López-Urrutia L; Quijada NM; Eiros JM
    Front Microbiol; 2018; 9():3331. PubMed ID: 30697203
    [No Abstract]   [Full Text] [Related]  

  • 56. An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.
    Cui Y; Zhang C; Jia Q; Gong X; Tan Y; Hua X; Jian W; Yang S; Hayer K; Raja Idris RK; Zhang Y; Wu Y; Tu Z
    BMC Infect Dis; 2023 Oct; 23(1):703. PubMed ID: 37858038
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Boyanova L; Dimitrov G; Gergova R; Hadzhiyski P; Markovska R
    Expert Rev Clin Pharmacol; 2023; 16(10):925-938. PubMed ID: 37642560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Butyrate Differentiates Permissiveness to Clostridioides difficile Infection and Influences Growth of Diverse C. difficile Isolates.
    Pensinger DA; Fisher AT; Dobrila HA; Van Treuren W; Gardner JO; Higginbottom SK; Carter MM; Schumann B; Bertozzi CR; Anikst V; Martin C; Robilotti EV; Chow JM; Buck RH; Tompkins LS; Sonnenburg JL; Hryckowian AJ
    Infect Immun; 2023 Feb; 91(2):e0057022. PubMed ID: 36692308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
    Stallhofer J; Steube A; Katzer K; Stallmach A
    Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diversity, Dynamics and Therapeutic Application of
    Nale JY; Thanki AM; Rashid SJ; Shan J; Vinner GK; Dowah ASA; Cheng JKJ; Sicheritz-Pontén T; Clokie MRJ
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560776
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.